who activities on influenza vaccine research
TRANSCRIPT
WHO activities on influenza vaccine research
Dr John S. Tam
Technical Officer
Initiative for Vaccine Research
Immunization, Vaccines and Biologicals
GAP-II: Further Research and Development | 13 July 2011, Geneva2 |
WHO Public health research agenda for influenza
1st Consultative meeting in 2009
WHO Public health research agenda for influenza
1st Consultative meeting in 2009
GAP-II: Further Research and Development | 13 July 2011, Geneva3 |
WHO Documents Highlighting The Importance of Research in Influenza
WHO Documents Highlighting The Importance of Research in Influenza
GAP-II: Further Research and Development | 13 July 2011, Geneva4 |
Influenza Research Priorities in Other Agencies and Organizations
Influenza Research Priorities in Other Agencies and Organizations
GAP-II: Further Research and Development | 13 July 2011, Geneva5 |
GOAL:
Support the development of evidences needed to strengthen
public health guidance and actions essential for limiting the
impact of influenza on individuals and populations
WHO Public health research agenda for influenzaWHO Public health research agenda for influenza
Stream 1. Reducing risk of emergence of pandemic
influenza
Stream 2. Limiting spread of pandemic, zoonotic and seasonal influenza
Stream 3. Minimizing impact of pandemic, zoonotic and seasonal influenza
Stream 4. Optimizing treatment of patients
Stream 5. Promoting development and application of
modern public health tools in influenza control
http://www.who.int/csr/disease/influenza/research_agenda/en/
GAP-II: Further Research and Development | 13 July 2011, Geneva6 |
Public Health Research Agenda for Influenza Stream 1. Reducing the risk of emergence of pandemic influenza
Public Health Research Agenda for Influenza Stream 1. Reducing the risk of emergence of pandemic influenza
Research Recommendations:
• Factors associated with the emergence of influenza viruses with zoonotic or pandemic potential
• Factors associated with human infection at the human-animal interface
• Preventive measures and surveillance at the human-animal interface
GAP-II: Further Research and Development | 13 July 2011, Geneva7 |
Public Health Research Agenda for Influenza Stream 2. Limiting the spread of influenza
Public Health Research Agenda for Influenza Stream 2. Limiting the spread of influenza
Research Recommendations :
• Factors associated with person-to-person
transmission
• Non-medical measures to limit transmission
• Dynamics of virus spread at global and local levels
GAP-II: Further Research and Development | 13 July 2011, Geneva8 |
Research Recommendations :
• Determining disease burden and social impact
• Improve immunogenicity, availability and delivery of influenza vaccines
• Public health policies to reduce the impact of disease
Public Health Research Agenda for Influenza Stream 3. Minimizing the impact of influenza
Public Health Research Agenda for Influenza Stream 3. Minimizing the impact of influenza
GAP-II: Further Research and Development | 13 July 2011, Geneva9 |
Research Recommendations :
• Factors associated with pathogenesis and clinical
severity
• Improve clinical management of patients
• Health care capacity and response
Public Health Research Agenda for Influenza Stream 4. Optimizing the treatment of patients
Public Health Research Agenda for Influenza Stream 4. Optimizing the treatment of patients
GAP-II: Further Research and Development | 13 July 2011, Geneva10 |
Research Recommendations :
• Modern tools for early detection and disease monitoring/surveillance
• Role of modelling in public health decision making
• Modern tools for strategic communication
Public Health Research Agenda for Influenza Stream 5. Development & application of modern public health tools
Public Health Research Agenda for Influenza Stream 5. Development & application of modern public health tools
GAP-II: Further Research and Development | 13 July 2011, Geneva11 |
Research Recommendations :
• Assessment of disease burden� Disease burden for epidemic influenza (developing regions, morbidity &
mortality by age and epidemiological settings)� Using disease burden data for health resource utilization planning
• Pharmacological interventions to reduce impact of disease� Development of new-generation vaccines (immunogen design, new
formulation, use of adjuvants)� Evaluation of vaccines� Increased pandemic vaccine production capacity � Development and evaluation of new antiviral drugs � Enhancing antiviral drug production capacity
• Public health policies to reduce impact of disease� Best practices for under-resourced countries� Social, ethical & legal considerations in public health policies development
Public health research agenda for influenza Stream 3. Minimizing the impact of influenza
Public health research agenda for influenza Stream 3. Minimizing the impact of influenza
GAP-II: Further Research and Development | 13 July 2011, Geneva12 |
Initiative for Vaccine Research (IVR)Initiative for Vaccine Research (IVR)
� Vaccine research and development monitoring
� Policy development research
� Operational research
� Implementation research
� Regulatory research
� Research agenda development
GAP-II: Further Research and Development | 13 July 2011, Geneva13 |
Landscaping on vaccine research and development:
� Annual meeting on Evaluation of Pandemic Influenza Vaccines in
Clinical Trials (7th meeting held on 17 - 18 February 2011 )
http://www.who.int/vaccine_research/diseases/influenza/flu_trials_tables/en/index.html
� Annual meeting on influenza vaccines that induce broad spectrum
and long-lasting immune responses (5th meeting to be held on 16-17
November 2011, Geneva) http://www.who.int/vaccine_research/diseases/ari/Influenza_meetings/en/
� Database on influenza vaccine clinical trial results for public
access through internet (http://www.who.int/vaccine_research/diseases/influenza/flu_trials_tables/en/index.html)
� Continued monitoring of global vaccine pipelines development
Vaccine Research and DevelopmentVaccine Research and Development
GAP-II: Further Research and Development | 13 July 2011, Geneva14 |
Global road-mapping for vaccination policy development and coverage - follow up actions:
� Develop regional workshops for vaccine policy development with all regional offices
� Continued monitoring of vaccine policy implementation and coverage
� Continued updates on acceptance and use of vaccines
� Monitor evidence supporting the use of adjuvanted vaccines and their safety
� Monitor evidence to support and review SAGE recommendations for influenza vaccine
Policy DevelopmentPolicy Development
GAP-II: Further Research and Development | 13 July 2011, Geneva15 |
� Research on optimum vaccine deployment strategy
� Identify optimum strategies for pandemic vaccine
stockpile management
Operational ResearchOperational Research
GAP-II: Further Research and Development | 13 July 2011, Geneva16 |
� Initiate and support vaccine effectiveness studies in
developing countries especially for grantee countries
� Initiate and support vaccine cost-effectiveness studies
especially for countries/regions developing vaccine
policies for influenza
Implementation ResearchImplementation Research
GAP-II: Further Research and Development | 13 July 2011, Geneva17 |
� Identify country-specific regulatory approval issues associated with influenza vaccine development particularly in grantee
countries
� Facilitate exchange of information on comparison of country-
specific regulatory approval issues associated with influenza vaccine and vaccine policy development
� Examine options for harmonization of regulatory requirements forinfluenza vaccines
� Develop regulatory pathways for novel influenza vaccine licensing
� Monitor and initiate research on correlates of protection in various influenza vaccines
Regulatory ResearchRegulatory Research
GAP-II: Further Research and Development | 13 July 2011, Geneva18 |
� Organize consultative meeting to develop Influenza Vaccine
Research Agenda and identify priority research areas on novel vaccine targets, production platforms, formulation and vaccine
delivery methods (SAGE WG)
� Develop plans and provide support for priority vaccine research
areas identified in the Research Agenda
� Align and support activities in the WHO Public Health Research
Agenda for Influenza (GIP)
Research Agenda for
Influenza Vaccine
Research Agenda for
Influenza Vaccine
GAP-II: Further Research and Development | 13 July 2011, Geneva19 |
Current ContextCurrent Context
IHR RC PIP
GAP
TechTransfer
R&D
VaccineVaccine
Antivirals
Diagnostics
Virus sharingSurveillance
Preparedness
Research agenda
Responds